Glioma
Glioma not effectively treated with recommended phase 2 dose of irinotecan
Published in Cancer Weekly, June 5th, 2006
"The purpose of this study was to determine the response to CPT-11 administered every 3 weeks to adults with progressive malignant glioma, treated with or without enzyme-inducing antiepileptic drug (EIAED) therapy, at the recommended phase 2 dose determined from a previous phase 1 study. Adult patients age 18 or older with a KPS of 60 or higher who had measurable recurrent grade III anaplastic glioma (AG) or grade IV glioblastoma multiforme (GBM) were eligible," researchers in the United States reported.
"No more than one prior chemotherapy was allowed, either...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2006-06-05)
More Articles from Cancer Weekly
- Complementary & Alternative Medicine
Cancer therapy efficacy increased by controlling meal timing - Leukemia
Leukemia may be treated by novel polycyclic aromatic hydrocarbons - Skin Cancer
Public health skin cancer prevention policies should prohibit UV tanning advertising to minors - Uveal Melanoma
Uveal melanoma imaging improved with a 3.0-T MRI using a surface coil - Allergy & Immunology
Rheumatoid arthritis drug linked to serious infections and cancers - Anal Cancer
Elevated anal squamous cell carcinoma risk linked to benign inflammatory anal lesions - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
